MTSR insider filing details $65.60 cash and CVR treatment
Rhea-AI Filing Summary
Metsera, Inc. (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer Inc.. At the merger’s Effective Time, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon specified milestones.
The reporting person’s holdings changed accordingly: 2,688 shares of common stock were disposed, leaving 0 shares beneficially owned. A restricted stock unit grant of 2,688 RSUs was reported; under the merger, RSUs were canceled and converted into cash equal to the cash amount per share times the RSU count and CVRs equal to the underlying shares, with these payments not subject to vesting. A stock option for 47,730 shares at $19.81 was canceled and exchanged for cash based on the excess of the cash amount over the exercise price, plus one CVR per underlying share. For unvested options, the cash and CVRs will vest on the first anniversary of closing, contingent on continued service.
Positive
- None.
Negative
- None.
Insights
Form 4 shows merger-driven cash and CVR treatment of equity.
The filing documents how Metsera equity converted at merger close: each share became $65.60 cash plus one CVR. Equity awards were canceled and exchanged for cash and CVRs per award mechanics. This is standard in cash acquisitions with contingent consideration.
For RSUs, payments equal to the cash amount per share times units and corresponding CVRs are not subject to vesting. For stock options, cash equals the excess of the cash amount over the exercise price times shares, plus CVRs per share; unvested awards’ consideration vests on the first anniversary of closing, subject to continued service. Actual holder proceeds depend on award counts and terms disclosed here.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 2,688 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 47,730 | $0.00 | -- |
| Disposition | Common Stock | 2,688 | $0.00 | -- |
Footnotes (1)
- Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are not subject to vesting. This option provided for vesting in 36 substantially equal monthly installments from April 28, 2025.
